Diabetes Clinical Trials in Wilmington
View 19 new treatments for Diabetes in Wilmington, NC. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Mifepristone for Type 2 Diabetes
Corcept Clinic, Wilmington + 1 more
This trial is testing mifepristone, a medication that blocks cortisol, in patients with hard-to-control type 2 diabetes and high cortisol levels. The goal is to see if mifepristone can help manage their blood sugar better than standard treatments alone. Mifepristone has been studied for various conditions including Cushing's syndrome, psychotic depression, and cognitive decline in Alzheimer's disease.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Daniel Einhorn, MD
Study Director
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Wilmington + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Clinical Trials
Study Director
BI 456906 for Diabetes and Obesity
Boehringer Ingelheim Clinic, Wilmington + 1 more
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Orforglipron for Type 2 Diabetes and Obesity
Eli Lilly Clinic, Wilmington + 1 more
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Retatrutide for Type 2 Diabetes
Eli Lilly Clinic, Wilmington + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Tirzepatide vs Dulaglutide for Type 2 Diabetes
Eli Lilly Clinic, Wilmington + 2 more
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
CagriSema for Type 2 Diabetes
Novo Nordisk Clinic, Wilmington + 1 more
This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
Hoffmann-La Roche Clinic, Wilmington + 1 more
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate the safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Trials
Study Director
Weekly vs Daily Insulin for Type 2 Diabetes
Novo Nordisk Clinic, Wilmington + 1 more
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Transparency (dept. 2834)
Study Director
Ertugliflozin for Pediatric Type 2 Diabetes
Merck Sharp & Dohme Clinic, Wilmington + 1 more
This study will evaluate the safety and efficacy of ertugliflozin pidolate (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin pidolate reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Medical Director
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions